Article Figures & Data
Figures
- Fig. 1.
A-B, comparison of maximal SUVs after i.v. and i.a. application, respectively, of 68Ga-DOTATOC in 122 liver metastases of 11 patients suffering from metastasized gastroenteropancreatic cancer (paired t test, P < 0.001). The main statistic is summarized as a box plot (A). The individual lesions are also presented in a scatter plot (B; note the different scales in X- and Y-axes). However, it was previously shown that vascular fraction and receptor binding are independent factors determining the SUV in DOTATOC-PET and therefore the linear regression analysis (line) might be insufficient to predict the benefit of a particular lesion.
- Fig. 2.
Comparison of intraindividual 68Ga-DOTATOC PET/CT in a patient with multiple liver metastases, presented as a maximum intensity projection after i.v. (A) versus i.a. (B) application. Average SUV(max) presents a 3.2-fold higher value (122.9 versus 38.5) after i.a. 68Ga-DOTATOC infusion. C, digital subtraction angiography illustrates the nearly exclusive arterial perfusion of neuroendocrine liver metastases.
- Fig. 3.
Patient with neuroendocrine cancer in the mesenteric root (P-NET) shown by contrast-enhanced CT (arrow, tumor lesion). After selective exploration of the gastroduodenal artery, tumor uptake was enhanced 7.8-fold (SUV 279.4 versus 35.7) after i.a. (C) in comparison with i.v. (B) injection of 68Ga-DOTATOC.
- Fig. 4.
DOTATOC biodistribution presented as maximum intensity projections. A, 68Ga-DOTATOC PET/CT in a patient with low tumor burden. The two solitary liver metastases (arrows) show enhanced uptake after arterial injection (right), whereas whole-body distribution (kidneys, spleen) did not differ significantly. B, 68Ga-DOTATOC PET/CT in a patient with high tumor burden of the liver. After i.v. application (left), the most intense uptake was seen inside the spleen and there is circumscribable uptake in the kidneys. After i.a. application, the main volume of DOTATOC was trapped in the liver metastases during the first-pass effect, whereas the uptake from the kidneys and spleen was decreased remarkably.
- Fig. 5.
NOA-B, comparison of maximal SUVs after i.v. and tumor-targeted i.a. application of 68Ga-DOTATOC in the pituitary gland (A) and kidney (B) of 15 patients suffering from gastroenteropancreatic neuroendocrine cancer. A significant decrease was shown for the pituitary gland (P < 0.05, paired t test), the reduction of kidney uptake only tends to be significant (P = 0.08, paired t test).
Volume 16, Issue 10
